Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.
Schwind unveiled its PresbyMAX software module at ESCRS, a presbyopia solution for its AMARIS system. According to Schwind, the software makes it possible, for the first time, to treat emmetropic as well as myopic, hyperopic and astigmatic patients whose accommodative response is limited.
In contrast to other methods of treating presbyopia, PresbyMAX delivers bi-aspheric multifocal ablation profiles. Bi-aspheric refers to aspheric optimisation of the central corneal area for near vision and the midperipheral cornea for far vision of each patient eye. Near vision of presbyopic patients, even with additional visual defects like distance refraction and high-order aberrations, is significantly improved, providing sharper vision without the need for spectacles.
The software was developed by Schwind in cooperation with VISSUM under the direction of editorial advisory board member, Prof. Jorge Alio, Spain, and the OCIVIS group from the University of Alicante. He said: “The central development goal of PresbyMAX was to provide the first systematic and scientifically based approach for the correction of presbyopia with excimer laser surgery.”
Similar to multifocal contact lenses or refractive multifocal IOLs, PresbyMAX creates a multifocal corneal surface. Bi-aspheric multifocal ablation profiles are optimised using a predictive model based on a light propagation algorithm.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.